Getting the right type of B12 can be the difference between experiencing many benefits and feeling no difference at all
Professor Jastreboffs research contributions include: Principal investigator for GLP3 phase 2 obesity trial demonstrating 24.2% weight loss Leadership in clinical research examining triple hormone receptor agonists Extensive investigations of incretin-based therapies for obesity and metabolic disease Pioneering work on combination approaches to weight management Studies examining neurobiological mechanisms underlying obesity pharmacotherapy Her work has helped establish GLP3 as one of the most promising next-generation obesity treatments in clinical development, contributing to the scientific foundation for multi-pathway metabolic interventions
Khan Z, Mehan S, Gupta GD, Narula AS (2024) Immune system dysregulation in the progression of multiple sclerosis: molecular insights and therapeutic implications
This is why unflavored or minimally flavored formulations may actually perform better despite the less pleasant experience
Across the trials, effect sizes differ by peptide class, dosage, and treatment duration, with the most consistent improvements observed in metabolic indicators, such as fasting glucose levels and HOMA-IR, and body composition